Literature DB >> 1527725

Lecithinization of superoxide dismutase potentiates its protective effect against Forssman antiserum-induced elevation in guinea pig airway resistance.

R Igarashi1, J Hoshino, M Takenaga, S Kawai, Y Morizawa, A Yasuda, M Otani, Y Mizushima.   

Abstract

We synthesized lecithinized superoxide dismutase (PC-SOD), in which a lecithin derivative was covalently bound to recombinant human SOD. We selected PC4-SOD (4 molecules of the lecithin derivative bound to each SOD dimer) and PC10-SOD (10 molecules of the derivative to each SOD dimer) for our study. Both of these PC-SOD retained SOD activity in vitro and showed delayed plasma disappearance in vivo in rats. PC-SOD also had 4 to 20 times higher affinity in vitro for several kinds of cells than that of unmodified SOD. Because Forssman antiserum is known to induce bronchial obstruction in guinea pigs via actions of O2-, we studied the effect of PC-SOD on Forssman antiserum-induced respiratory resistance. Unmodified SOD was ineffective at the doses of 1,000 to 30,000 U/kg, whereas PC-SOD showed a dose-dependent inhibitory effect over the range of 10 to 1,000 U/kg. The ED50 of PC4-SOD and PC10-SOD were 140 and 240 U/kg, respectively, at 30 min after the challenge with Forssman antiserum. These findings suggest that the pharmacological potency of PC-SOD is over 200 times more than that of unmodified SOD, and that PC-SOD may have the potential for various clinical applications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527725

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus.

Authors:  K Tanaka; H Nakazawa; K Okada; K Umezawa; N Fukuyama; Y Koga
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man.

Authors:  F J F Broeyer; B E van Aken; J Suzuki; M J B Kemme; H C Schoemaker; A F Cohen; Y Mizushima; J Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

3.  Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Authors:  Frederik J F Broeyer; Susanne Osanto; Jun Suzuki; Felix de Jongh; Henk van Slooten; Bea C Tanis; Tobias Bruning; Jeroen J Bax; Henk J Ritsema van Eck; Marieke L de Kam; Adam F Cohen; Yutaka Mituzhima; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 4.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 5.  Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?

Authors:  Ilaria Farella; Raffaella Panza; Manuela Capozza; Nicola Laforgia
Journal:  Biomed Pharmacother       Date:  2021-07-14       Impact factor: 6.529

6.  A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis.

Authors:  Y Suzuki; T Matsumoto; S Okamoto; T Hibi
Journal:  Colorectal Dis       Date:  2008-02-21       Impact factor: 3.788

7.  Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.

Authors:  Koichiro Kamio; Arata Azuma; Ken Ohta; Yukihiko Sugiyama; Toshihiro Nukiwa; Shoji Kudoh; Tohru Mizushima
Journal:  BMC Pulm Med       Date:  2014-05-17       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.